VivoSeq
Oncology

Metastatic Neoplasm

7

Pipeline Programs

1

Active Trials

6

Companies Involved

Metastatic Neoplasm is an early-stage landscape with 7 programs across 6 companies. The most active players are Merck & Co., Regeneron, AstraZeneca.

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Modality Breakdown

7programs
Monoclonal antibody457%
Small molecule343%

Modality classified for 100% of 7 pipeline programs.

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)